Author

Guillaume Jacquot

Institut de Cancérologie StrasbourgPrimary ORCID profile (0009-0006-4352-1609 · 5 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Guillaume JacquotiD5 papers

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

Alexandre DetappeiD· 2 shared Céline MirjoletiD· 2 shared Julien Draussin· 2 shared Mark W. TibbittiD· 2 shared Sébastien HarleppiD· 2 shared Stéphane BernhardiD· 2 shared Xavier B. PivotiD· 2 shared Adeline GasseriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alexandre DetappeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Hydrogel confinement enables subcutaneous delivery of vesicant antibody-drug conjugates

Guillaume Jacquot, Capucine Hervy, Elies Belarouci, Adeline Gasser, Chawin Hoernel, Olga Traissard, María Gutiérrez‐Blanco, Julien Draussin, Stéphane Erb, Susana Brun, Lyne Fellmann, Joris Mallard, Elyse Hucteau, Pierre Coliat, Stéphane Bernhard, , Alexandre Detappe

This paper develops a hydrogel that enables subcutaneous delivery of vesicant antibody-drug conjugates by confining them in a depot, reducing tissue damage while maintaining antitumor efficacy.

bioRxiv · May 27, 2026 · PreprintCancer Biology

Reinforced polymer-nanoparticle hydrogels for subcutaneous and sustained delivery of trastuzumab

Giovanni Bovone, Stéphane Bernhard, Guillaume Jacquot, Vincent Mittelheisser, Céline Mirjolet, Elia A. Guzzi, Lorenza Garau Paganella, Luca Liebi, Julien Draussin, Pedro Lopez Navarro, Elsa Barbé, Olivier Lefèbvre, Jacky G. Goetz, Loı̈c J. Charbonnière, Xavier B. Pivot, , Alexandre Detappe

This paper develops a hydrogel platform for subcutaneous delivery of trastuzumab, achieving sustained release over 3 days in vitro and in vivo.

Advanced Healthcare Materials · Jun 9, 2025Peer-reviewedBioengineering